Patents by Inventor Andrew J. Garton

Andrew J. Garton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT
    Publication number: 20090136517
    Abstract: The present invention provides a composition and a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and a KIT kinase inhibitors, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEVA®). A preferred example of a KIT kinase inhibitor that can be used in practicing this invention is OSI-930 and OSI-817.
    Type: Application
    Filed: November 26, 2008
    Publication date: May 28, 2009
    Inventors: Andrew J. Garton, Maryland Franklin
  • Method for the assay of rock kinase activity in cells
    Publication number: 20070231838
    Abstract: The present invention provides a method for determining the intracellular activity of ROCK kinase comprising, providing a sample of cells to be tested for ROCK kinase activity, determining the level of phosphorylation of MYPT1 in the sample, and determining the intracellular activity of ROCK kinase in the sample of cells, wherein the level of MYPT1 phosphorylation directly correlates with the level of intracellular ROCK kinase activity.
    Type: Application
    Filed: April 3, 2007
    Publication date: October 4, 2007
    Inventors: Andrew J. Garton, Linda Castaldo